Canadian Guidelines for Chronic Rhinosinusitis: Clinical Summary
Overview
Public Health
Authors
Affiliations
Objective: To provide a clinical summary of the Canadian clinical practice guidelines for chronic rhinosinusitis (CRS) that includes recommendations relevant for family physicians.
Quality Of Evidence: Guideline authors performed a systematic literature search and drafted recommendations. Recommendations received both strength of evidence and strength of recommendation ratings. Input from external content experts was sought, as was endorsement from Canadian medical societies (Association of Medical Microbiology and Infectious Disease Canada, Canadian Society of Allergy and Clinical Immunology, Canadian Society of Otolaryngology-Head and Neck Surgery, Canadian Association of Emergency Physicians, and Family Physicians Airways Group of Canada).
Main Message: Diagnosis of CRS is based on type and duration of symptoms and an objective finding of inflammation of the nasal mucosa or paranasal sinuses. Chronic rhinosinusitis is categorized based on presence or absence of nasal polyps, and this distinction leads to differences in treatment. Chronic rhinosinusitis with nasal polyps is treated with intranasal corticosteroids. Antibiotics are recommended when symptoms indicate infection (pain or purulence). For CRS without nasal polyps, intranasal corticosteroids and second-line antibiotics (ie, amoxicillin- clavulanic acid combinations or fluoroquinolones with enhanced Gram-positive activity) are recommended. Saline irrigation, oral steroids, and allergy testing might be appropriate. Failure of response should prompt consideration of alternative diagnoses and referral to an otolaryngologist. Patients undergoing endoscopic sinus surgery require postoperative treatment and follow-up.
Conclusion: The Canadian guidelines provide diagnosis and treatment approaches based on the current understanding of the disease and available evidence. Additionally, the guidelines provide the expert opinion of a diverse group of practice and academic experts to help guide clinicians where evidence is sparse.
Cui J, Lin W, May B, Luo Q, Worsnop C, Zhang A PLoS One. 2023; 18(10):e0292138.
PMID: 37797052 PMC: 10553817. DOI: 10.1371/journal.pone.0292138.
Sudiro M, Kuntara A, Waldi D Acta Inform Med. 2023; 31(1):53-56.
PMID: 37038495 PMC: 10082653. DOI: 10.5455/aim.2023.31.53-56.
Chinese herbal therapy in the management of rhinosinusitis-A systematic review and meta-analysis.
Cui J, Lin W, May B, Luo Q, Worsnop C, Zhang A PLoS One. 2022; 17(12):e0278492.
PMID: 36454862 PMC: 9714754. DOI: 10.1371/journal.pone.0278492.
Improving predictability of IgE-high type 2 chronic sinusitis with nasal polyps in the biologic era.
Heffernan A, Phulka J, Thamboo A J Otolaryngol Head Neck Surg. 2022; 51(1):22.
PMID: 35606866 PMC: 9128111. DOI: 10.1186/s40463-022-00580-y.
Cystic Fibrosis Foundation otolaryngology care multidisciplinary consensus recommendations.
Kimple A, Senior B, Naureckas E, Gudis D, Meyer T, Hempstead S Int Forum Allergy Rhinol. 2022; 12(9):1089-1103.
PMID: 35089650 PMC: 9545592. DOI: 10.1002/alr.22974.